B A C K G R O U N D
A glossary of terms is available as an appendix (Appendix 1).
Description of the condition
Genetic medicine is expanding into almost every aspect of health care; reproductive risk assessment during the preconception period is a prime example. Identifying genetic risks before pregnancy or conception might produce significant benefits, such as providing information about the risk of having children with genetic conditions and thus giving couples or prospective parents the opportunity to make more informed reproductive decisions. It has been estimated that a couple has a baseline risk of two to three per cent of having a child with a congenital or genetic disorder (Teeuw 2010). The probability of having an affected child increases when there is a family history of genetic disorders (Shapira 2006; Teeuw 2010) . Globally, about five per cent of children are born with congenital or genetic disorders (WHO 1999) . Preconception risk assessment for autosomal recessive genetic disorders would benefit couples who may be carriers. The most common examples of these autosomal recessive disorders are thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease. In these disorders, such carriers are usually asymptomatic; however, their child will be affected if he or she inherits the affected genes from both parents. All carrier couples have a 25 per cent chance of having an affected child. These conditions have a high morbidity risk, are potentially life-threatening and have a significant psychological impact not only on the affected child, but also on their families or care givers. These diseases are also more prevalent in individuals of particular ethnic backgrounds (WHO 2000) . The need for medical care, as well as psychological interventions to offer behavioural and emotional support, imposes a potentially high economic and public health burden. In view of the magnitude of these conditions and their implications, there have been considerable efforts to identify the genetic reproductive risk for the four specified conditions and offer support to potential parents before the birth of an affected child. Women and couples at increased genetic risk, as well as healthcare professionals, have recognised the importance of preconception assessment (Boulton 1996 
Thalassaemia
According to the WHO, every year 300,000 infants are born with major haemoglobin disorders, the most common being thalassaemia and sickle cell disease (WHO 1999) . Thalassaemia is characterised by the defects or absence of synthesis in one of the two globin chains (α or β) which form the normal adult human haemoglobin molecule; this leads to haemolytic anaemia (Peters 2012). Thalassaemia can be diagnosed by measuring fractions of haemoglobin A and haemoglobin F with high performance liquid chromatography (HPLC) or electrophoresis. In addition, DNA analysis is required to detect an α or β globin chain mutation (Peters 2012). It is estimated that between two and five per cent of the world's population are carriers and this is more prevalent in the Mediterranean and Southern Asian populations (Modell 2001) . Morbidity is related to severe anaemia and an affected child will require lifelong blood transfusions. Multiple blood transfusions may eventually result in iron overload and potentially cause heart failure, infection, hypogonadism, infertility, diabetes mellitus, and hypothyroidism. Affected individuals may die prematurely, unless given optimal medical management. In individuals with thalassaemia and their families or care givers, psychosocial problems have also been reported, for example stigmatisation, isolation, family adjustment, coping with school and education, and social interaction (Gharaibeh 2009; Ratip 1996; Telfer 2005).
Sickle cell disease
Sickle cell disease is caused by a mutation in the haemoglobin gene (β S ) which individuals inherit from both parents (Weatherall 1997) . The WHO estimates that sickle cell disease affects 275,000 conceptions each year globally (Modell 2008; Yusuf 2011). Diagnosis is confirmed using HPLC or electrophoresis with the detection of haemoglobin S and C fraction. It affects mainly individuals of African origin, but is also found in Indian and some Mediterranean populations. The reported prevalence of carrier frequency ranges from one to 40 per cent, depending on the population group. The condition causes the red blood cells to have a sickle shape which results in premature haemolysis, and can lead to lifethreatening acute and chronic vaso-occlusion, including renal and cardiovascular complications. Individuals with this condition are also susceptible to serious septicaemia. Like thalassaemia, individuals and their families are also confronted with psychosocial challenges which include the disruption of school and work, social isolation and loneliness, stigmatisation, bullying, and rejection by peers (Barbarin 1999).
Cystic fibrosis
Cystic fibrosis is caused by a mutation in the gene cystic fibrosis transmembrane conductance regulator (CFTR); more than 1500 CFTR mutations have now been identified. Diagnosis of cystic fibrosis is indicated by phenotypic features (chronic sino-pulmonary disease, gastrointestinal and nutritional abnormalities, obstructive azoospermia and salt-loss syndromes), a family history of cystic fibrosis or a positive newborn screening test, together with laboratory evidence of a CFTR abnormality. Abnormalities in the CFTR can be identified by elevated sweat chloride concentrations (sweat test), identification of two CFTR mutations, or in vivo demonstration of characteristic abnormalities in ion transport across the nasal epithelium. Carriers are confirmed by identification of a CFTR mutation from the blood or saliva (CDC 2004). Cystic fibrosis is most common among people of European descent with a carrier frequency of 1 in 25 (Murray 1999). This condition is commonly associated with recurrent pulmonary infections, which potentially lead to bronchiectasis and atelectasis, and also pancreatic exocrine insufficiency. There is currently no cure for the disease, with treatment mainly aimed at improving a person's quality of life. The need for emotional and social adjustment is a significant psychosocial consequence for people with cystic fibrosis (Bregnballe 2007; Glasscoe 2008). In addition, poor adherence to treatment has also been reported due to the burden of treatment and the long-term management of the condition (Abbot 1996).
Tay-Sachs disease
Tay-Sachs disease is caused by a genetic mutation in the α chains of the hexosaminidase A (Hex A) isozyme in the gangliosides in nerve cells of the brain (Bach 2001). The disease is diagnosed by measuring the activity of hexosaminidase A and further identification of a genetic mutation in Hex A (ACOG Committee Opinion 2005). It is most prevalent in the Ashkenazi Jewish and French Canadian populations, with a carrier frequency of around 1 in 30 (Petersen 1983; Palomaki 1995). The condition leads to a progressive deterioration of mental and physical abilities. Death usually occurs before five years of age. At present, there is no cure or available treatment.
Description of the intervention
Women and their partners can be assessed during the preconception period to identify if they are carriers of one of these four autosomal recessive conditions. These four conditions represent the most common autosomal recessive conditions globally. Cystic fibrosis is most common in Northern European populations; sickle cell disease and thalassaemia are most common non-Northern European populations, and Tay-Sachs disease is most common in individuals of Ashkenazi Jewish and French Canadian ancestry. Approaches to improve health outcomes and reproductive choice in couples who carry these genetic conditions should be generalizable to other, but rarer, autosomal recessive conditions. In populations with high carrier rates or significant burden of affected individuals, or both, carrier screening may be offered during preconception to all women in some healthcare settings (PFASP England 2013). More commonly, women and their partners may be assessed on the need for carrier testing. This assessment would be based firstly on a review of the family history for any of the autosomal recessive conditions or their carrier status; and, secondly, on the ethnic origin of the woman and her partner (Dyson 2006) . This assessment of ancestry will identify if the individual originates from an ethnic group with a greater probability of being a healthy carrier of any of the four autosomal recessive disorders; for example those with Ashkenazi Jewish ancestry are more likely to carry Tay-Sachs disease, whilst those of African descent may carry sickle cell trait. The benefits of recording family history as one of the components of preconception health checks have been reported in previous observational community-based studies for a broad range of genetic conditions in both the United Kingdom (Rose 1999) and Hungary (Czeizel 2012 
How the intervention might work
In the specified autosomal recessive disorders (thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease), preconception genetic risk assessment ensures at-risk couples, in which both the women and her partner are carriers of the specified conditions, are aware that they have a one in four chance of an affected child prior to pregnancy, enabling them to make fully informed repro- However, a comprehensive review of the current evidence still needs to be undertaken to directly inform healthcare practice. This review will explore if robust trial evidence exists on the effect of preconception genetic risk assessment for genetic disorders, particularly before its widespread routine implementation in current healthcare settings.
Why it is important to do this review

O B J E C T I V E S
The purpose of this review is to assess the effectiveness of systematic preconception genetic risk assessment to improve reproductive outcomes in women and their partners who are identified as carriers of thalassaemia, sickle cell disease, cystic fibrosis or TaySachs disease in healthcare settings, when compared to usual care.
M E T H O D S Criteria for considering studies for this review Types of studies
We planned for this review to include all relevant randomised controlled trials (RCTs) and quasi-randomised controlled trials (quasi-RCTs).
Types of participants
Women and their partners of reproductive age (aged 16 to 50 years old) who are carriers for thalassaemia, sickle cell disease, cystic fibrosis or Tay-Sachs disease, accessing any healthcare services which include hospitals and community-based healthcare settings. Community-based healthcare settings include family or general practices, community health centres, community health services, community or outpatient clinics and ambulatory care services. Settings outside of healthcare do not directly inform healthcare practice, and thus will be excluded as being outside the scope of this review. If trials contain both eligible and ineligible participants, they will be included if data on eligible participants can be extracted.
Types of interventions
We planned to assess the effects of systematic preconception genetic risk assessment for thalassaemia, sickle cell disease, cystic fibrosis or Tay-Sachs disease, in any healthcare setting. We define systematic preconception genetic risk assessment as a package of risk assessment including one or more of these components:
• family history assessment;
• assessment of ethnicity background;
• genetic carrier testing;
• genetic carrier screening.
Risk assessment can be offered at anytime prior to conception. We planned to compare systematic preconception genetic risk assessment with standard care. We define standard care as where people receive usual or alternative care in any healthcare setting, that does not involve a specific systematic approach to preconception genetic risk assessment.
Types of outcome measures
The listed outcomes do not form part of the eligibility criteria for the included trials.
Primary outcomes
1. Reproductive outcomes in women and their partners who are carriers of thalassaemia, sickle cell disease, cystic fibrosis or Tay-Sachs disease identified during or after pregnancy i) number of infants born with genetic conditions ii) number of infants born with congenital anomalies iii) number of infants born with low birth weight iv) number of infants born prematurely 2. Decisions about future conception and pregnancy in women and their partners who are carriers for thalassaemia, sickle cell disease, cystic fibrosis or Tay-Sachs disease i) number of women or couples who would make use of prenatal diagnosis ii) number of women or couples who would make use of prenatal diagnosis and consider termination of pregnancy if the child is affected iii) number of women or couples who would consider pre-implantation genetic diagnosis and in vitro fertilization iv) number of women or couples who would conceive using donated gametes v) number of women or couples who would consider adoption vi) number of women or couples who would refrain from having any children
Secondary outcomes
1. During pregnancy following intervention i) gestational date of prenatal diagnosis in at-risk women ii) gestational date of prenatal counselling in at-risk women or couples 2. Self-reported measures (short-term change from baseline) i) any objective measures of health-related quality of life resulting from preconception genetic risk assessment, using validated tools such as Short Form Health Survey 36 (SF36) and Health Questionnaire EQ-5D
ii) any objective measures of quantifying psychological or social outcomes or both resulting from preconception genetic risk assessment using validated tools such as Spielberger State-Trait Anxiety Inventory (STAI), Perceived Stress Questionnaire (PSQ)
iii) knowledge (any measures of the women's or couples' or both, knowledge of reproductive genetic risk associated with carrier status for thalassaemia, sickle cell disease, cystic fibrosis or Tay-Sachs disease using validated self-reported questionnaire) iv) satisfaction (any measures of the women's or couples' or both, satisfaction with the intervention using validated selfreported questionnaire) 3. Cost of the intervention (including follow-up visits and tests)
Search methods for identification of studies
We did not apply language restrictions in the electronic searches. If we identify potentially eligible non-English language trials in future searches, we will source a person who can read the language in order to assess these trials for possible inclusion and data extraction.
Electronic searches
We sought trials from the relevant Cystic Fibrosis and Genetic Disorders Group's Trials Registers using the terms: (carrier* OR trait OR risk assessment OR Tay We searched the following clinical trial databases for ongoing and unpublished trials:
• National Institutes of Health database;
• Clinical Trials Search Portal of the World Health Organization;
• Current Controlled Trials in the metaRegister of controlled clinical trials
Searching other resources
We planned to examine the reference lists of eligible published trials to identify further relevant trials. We hand searched the key journals European Journal of Human Genetics, Genetics in Medicine and the Journal of Community Genetics from 1998 to 06 January 2014. We complemented the search by contacting subject experts or centres in the field to request any unpublished or other published trials that we may not have identified.
Data collection and analysis
Selection of studies
We saved the results of the searches in the Endnote reference managing software (EndNote X3). Two review authors (one content expert and one methodologist) independently screened the citations and article abstracts of every retrieved record. We would have resolved any disagreements on eligibility by discussion and if doubt remained, we would have acquired the relevant full article(s) for further inspection. Two review authors independently screened all full text articles of the eligible trials. We aimed to resolve any disagreement by discussion. If required, we would have consulted a third review author. If necessary, we planned to contact the authors of the articles for further information and clarification of trials. We have reported reasons for excluding trials and provided a PRISMA flowchart (Figure 1 ).
We did not identify any trials for inclusion in this version of the review. However, if we identify any trials for future updates of the review, we plan to undertake the following.
Data extraction and management
Two review authors will independently extract data from each included trial using an agreed data extraction form. We will collect data on trial population characteristics (including sample size, participants' ethnic or cultural characteristics, geographic locations), intervention characteristics (including process and duration of intervention) and primary and secondary outcome measures of interest. We plan to report short-term outcomes post intervention up to six months. We plan to report long-term outcomes post intervention from six months up to 12 months, and then annually thereafter. We will settle any disagreements about the data extracted through discussion by the two review authors, and if necessary by arbitration with a third author. We will enter all the data into the Review Manager software (RevMan 2014).
Assessment of risk of bias in included studies
We will construct a risk of bias table for each trial as outlined in chapter 8 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). Two review authors will independently assess and record the following six domains in the risk of bias table:
1. random sequence generation; 2. allocation sequence concealment; 3. blinding of participants, trial personnel, outcome assessors; 4. incomplete outcome data; 5. selective outcome reporting; 6. other sources of bias. We will judge the methods used in the trials for each domain as having either a low, high or unclear risk of bias. Two review authors will aim to resolve any disagreements in the judgement of the domains through discussion. If no agreement can be reached, then they will consult a third author and aim to resolve the disagreement by consensus. We will record the information in the 'Risk of bias' tables in Review Manager (RevMan 2014). We aim to resolve any disagreement by consensus or arbitration by a third author. We will use the results of the risk of bias assessment to provide an evaluation of the overall risk of bias of the included trials based on the approach outlined in the chapter 8 (Table 8. 
7a) of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).
Measures of treatment effect
We will extract all the main results of the included trials as mentioned below. We will contact relevant authors of the original reports for data or any missing relevant information or when clarification is needed. We will settle any disagreements about the data extracted through discussion and if necessary by arbitration by a third author. We will enter all the data into the Review Manager software (RevMan 2014).
Continuous data
For scale-derived data, we will include continuous data from rating scales only if the measuring instrument has been validated. We will include endpoint data and only use change data if the former are not available. For continuous outcomes we will record mean, standard deviation (SD) and number of participants for each group and report effect size using the mean difference (MD) for the same units of measurement or the standardised mean difference (SMD) when different scales are used to evaluate the same outcome, with 95% confidence intervals (CI). The MD measures the absolute difference between the means in two groups, whereas the SMD is the MD relative to variability observed in that trial.
Dichotomous data
We will report dichotomous data using the risk ratio (RR) and the corresponding 95% CIs.
Unit of analysis issues
We anticipate cluster-randomised designs to be used in the included trials; for example, groups of patients of a single doctor or practice. If available, we will extract the direct estimate of the effect (RR with CI) that accounts for a cluster design. We will contact the primary authors of the included trials to obtain the intra-cluster correlation coefficient (ICC) which will describe the relative variability within and between clusters, to adjust for clustering effect (Donner 1980). We will meta-analyse the appropriate analyses of cluster randomised trials using the generic inverse variance method. Alternatively, we will estimate an ICC to describe the relative variability within and between clusters (Donner 1980). An ICC usually derives from the trial or from other sources (ICC from a similar trial in an existing database) (Ukoumunne 1999). If the ICC is derived from other sources, we will report this and conduct a sensitivity analysis. If the trials were analysed as if the randomisation was performed on the individuals rather than the clusters, we will re-calculate the correct analysis if we are able to extract the following information: the number of clusters randomised to each intervention group; the mean size of each cluster; and the outcome data ignoring the cluster design for the total number of individuals.
If we identify more than one intervention group of interest in a trial, we will analyse the effect of the additional intervention group using pair-wise comparisons. If the additional intervention group is irrelevant, we will not reproduce the data.
Dealing with missing data
Whenever possible, we will contact the original investigators and the authors of the included trials to request any missing data. If this is unsuccessful we will deal with missing data as mentioned below.
Overall loss of credibility
We will choose that, if for any particular outcome there is a high risk bias for missing data according to the risk of bias assessment, we will not use these data in the analyses and will present the results in the form of a narrative synthesis.
Continuous data
If SDs are not reported or available, we will first look for statistics that allow the calculation of the SD (for example, the CI and the standard error (SE) of group means, as well as P values and T values for the differences in means). If this is not possible, we will consider imputing SDs of other included trials. We will examine the consequences of imputations in a sensitivity analysis.
Assessment of heterogeneity
Clinical heterogeneity
We will consider clinical heterogeneity which can result from differences between trials in characteristics of the populations, interventions and outcomes. We will fully discuss the influence of clinical heterogeneity on the observed effects.
Methodological heterogeneity
We will assess for methodological heterogeneity, which can result from differences in characteristics of the trial designs. We will fully discuss the influence of methodological heterogeneity on the observed effects.
Statistical heterogeneity
We plan to examine graphs or summary tables of the trials to investigate the possibility of statistical heterogeneity. We plan to consider the I 2 statistic which estimates the proportion of variability in effect estimates that is due to heterogeneity (Higgins 2002). We will determine the level of heterogeneity by the following reference ranges: low 0% to 40%; moderate 41% to 75%; and high 76% to 100%. We also plan to use the Chi 2 statistic and if the P value is less than 0.10 it will be considered an indication of heterogeneity. If there is a high level of heterogeneity between trials, it may not be appropriate to conduct a meta-analysis, thus we will present results in a qualitative analysis. These trials will be entered into RevMan and presented on a forest plot with their individual effect sizes, but with no combined effect to give an overall picture of evidence (RevMan 2014).
Assessment of reporting biases
If the review includes more than 10 trials, we will create a funnel plot to investigate the possibility of small trial effects (a tendency for the intervention effects estimated in smaller trials to differ from those estimated in larger trials) (Sterne 2011).
Data synthesis
We will summarise all trials using narrative synthesis methods. This will involve the use of narrative text and tables to summarise data, consider outcomes in the light of differences in trial designs and address potential sources of bias for each of the trials being reviewed. We will group trials according to types of genetic conditions, and then organise them in terms of intervention and outcomes. We will summarise the results of the trials, including the range and size of any reported associations and important trial characteristics. We will also include a detailed commentary on the major methodological problems or biases affecting the trials, together with a description of how these may have affected the individual trial results. We will use a random-effects model to conduct the meta-analysis due to anticipated differences between trial location and population. If there is substantial variation in results, particularly if there is inconsistency in the direction of effect, we will not perform a meta-analysis.
Subgroup analysis and investigation of heterogeneity
The authors will perform subgroup analyses where sufficient data are available. In the subgroup analyses, the authors will analyse the data in pre-specified subgroups of trials that share characteristics of interest, to see whether the intervention effect remains consistent or whether it varies for particular characteristics of trials. For this review, the authors aim to compare the effects of interventions on outcome measures in the following groups by:
• healthcare setting (primary, secondary, tertiary care or other);
• intensity of the intervention (number or duration of intervention sessions);
• nature of carrier status testing (confirmed genetic carrier status compared to probable carrier status);
• type of condition.
Sensitivity analysis
If there is a spread of bias across the trials, we will provide two estimates of the intervention effect; firstly for all included trials, and secondly only including trials with an overall assessment of a low risk of bias.
R E S U L T S Description of studies
Results of the search
Database searching identified 4207 records. After screening 2695 unique records, 22 full-text articles describing 14 unique trials were retrieved for further analysis. No RCTs were found that were eligible for inclusion in the review. A flow diagram illustrates the search flow process (Figure 1 ).
Included studies
No RCTs were found to be eligible for inclusion in the review.
Excluded studies
Ten studies were excluded due to non-RCT study designs 
Risk of bias in included studies
No trials were included in this review.
Effects of interventions
No trials were eligible for inclusion in this review.
D I S C U S S I O N
Summary of main results
Identifying those couples before pregnancy, who have a confirmed genetic carrier status for thalassaemia, sickle cell disease, cystic fibrosis, or Tay-Sachs disease may provide the opportunity for individuals or couples to make fully informed reproductive choices such as avoiding pregnancy, pre-implantation diagnosis, in vitro fertilisation, arranging early prenatal diagnosis, or consideration of adoption. However, there is currently no evidence from randomised controlled trials (RCTs) for the impact of genetic risk assessment for these conditions in non-pregnant women on pregnancy outcomes, informed reproductive choices or psychological adverse effects.
Overall completeness and applicability of evidence
To date, in many countries, reproductive genetic risk assessment for autosomal recessive disorders has focused on the antenatal period and carrier status that has emerged as an incidental finding in neonatal screening. In the antenatal period, carrier status is identified either through formal screening programmes, or opportunistically during antenatal follow up in women at increased risk based on ancestry. During the antenatal period, if both parents are found to be carriers of the genes (at-risk couples), prenatal diagnostic tests, such amniocentesis, may only be available either late in the first trimester or in the second trimester of pregnancy, which leaves the couple only a short period of time to make limited and difficult choices about termination or continuation of the pregnancy. , whilst no studies have assessed actual reproductive outcomes. The limited duration of follow up in these studies would make assessment of latter outcomes unrealistic. All of the above studies have assessed psychological, attitudes, or knowledge outcomes, but there was some heterogeneity in these outcomes between and within studies. Further, none of the outcome measures for knowledge had used validated instruments. Although study participants recognised the importance of identifying genetic carrier states before pregnancy, different attitudes towards genetic testing were elicited and reproductive intentions varied following positive test results. In the Netherlands, study participants would consider prenatal diagnosis and abortion if an affected foetus is identified (Henneman 2001). In contrast, in the US state of Tennessee in a study of cystic fibrosis screening, reproductive intentions were limited by cultural and socio-political factors, such as, insurability, being labelled as 'at risk', a lack of understanding, and religious beliefs about abortion (Clayton 1996). In addition, barriers to implementation may be due to fears of stigma ( Similarly the Health Council of Netherlands has recognised the seriousness of these conditions and high prevalence in local population groups, advocating preconception genetic risk assessment for cystic fibrosis, sickle cell and thalassaemia (Health Council of Netherlands 2007). However, the paucity of high quality studies limits the justification for national implementation. The WHO's Regional Office of Eastern Mediterranean recommend preconception genetic risk assessment for sickle cell and thalassaemia ideally before marriage, taking account of the sociocultural issues in the region, in particular religious reservations towards termination of pregnancy (Alwan 1997). Since the 1970s, the Cyprus Thalassaemia Control Programme has been at the forefront of premarital genetic screening and this has contributed to a fall in the prevalence of thalassaemia in the country (Angastiniotis 1981). This universal premarital approach to thalassaemia carrier screening has also been adopted by Sardinia, Italy (Cao 1996) and Greece (Loukopoulos 1996) . In line with international policy recommendations, the UK Human Genetics Commission has recognised that since antenatal screening is currently already offered for genetic conditions such as sickle cell disease and thalassaemia, there are no ethical, legal or social issues with regards to the implementation of a preconception screening programme which would provide the advantage of improving reproductive choices (Human Genetics Commission 2011). In South East Asia, the Family Planning Association of Hong Kong has recognised the benefits of preconception screening of genetic risk due to the high prevalence of thalassaemia carriers, accounting for up to eight per cent of the local population (Lau 1997). In the absence of high quality randomised controlled trials of preconception genetic risk assessment, as demonstrated in this systematic review, international policy makers must base recommendations on observational studies and consensus agreements.
Quality of the evidence
It has been suggested that the optimum evidence to evaluate the reproductive and psychological outcomes as a result of preconception screening, compared to standard practice, is a systematic review of RCTs, or a high quality RCT with a large enough sample size to ensure the control of potential confounding factors (National Screening Committee 2003). Such trials address methodological issues that are particularly associated with screening interventions such as ascertainment bias due to non-randomisation, with individuals joining screening programmes tending to have healthier lifestyles and better adherence to interventions (Smith 2003) . In addition, none of the excluded studies identified in the searches for this review have evaluated reproductive outcomes. This is possibly related to the limited duration of follow up in these studies. Although preconception genetic carrier tests and screening have been shown to be to highly accurate and efficient in determining carrier status (Bach 2001; CDC 2004; Peters 2012; Weatherall 1997), the effectiveness of such interventions is ultimately measured by their ability to reduce morbidity and mortality of the diseases. Therefore, reproductive outcomes are essential to addressing this question. Since this systematic review shows that there is a complete lack of RCTs in the field of preconception genetic risk assessment for autosomal recessive conditions, healthcare providers need to assess whether the information provided in published policy recommendations and non-randomised studies is relevant to inform their preconception screening practice. Furthermore, healthcare providers have to balance the benefits of increasing reproductive choice against the potential psychological adverse effects from preconception genetic risk assessment, whilst taking into account the legal and socio-cultural context of their healthcare setting and patient population.
The review authors have attempted to limit the bias in the review process through multiple authors and non-author contributors who independently searched for trials, screened titles and abstracts, selected full-text articles and extracted data. Any disagreements were resolved by group discussion and consensus, and therefore it was unlikely that trials have been incorrectly excluded. Although all clinical trials should be registered, there is always the potential of publication bias. However, attempts have been made to minimise publication bias through searching the grey literature and contacting key experts in the field.
Agreements and disagreements with other studies or reviews
This is the only systematic review looking at preconception genetic risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease and there were no randomised controlled trials eligible for inclusion, and therefore no comparisons could be made to other reviews or studies.
A U T H O R S ' C O N C L U S I O N S Implications for practice
No RCTs of preconception genetic risk assessment for thalassaemia, sickle cell disease, cystic fibrosis, or Tay-Sachs disease were found for inclusion in this review. Therefore, the research evidence on which to base clinical decisions is limited to non-randomised studies, which have largely formed the basis for current policy recommendations.
We have not identified any relevant trials up to most current search date 10 December 2014.
Implications for research
Previous observational studies and RCTs on preconception genetic risk assessment for thalassaemia, sickle cell disease, cystic fibrosis, or Tay-Sachs disease have been limited by duration of follow up and to assessment of psychological or knowledge outcomes. Adequately-powered RCTs assessing reproductive outcomes (number of affected children born with genetic conditions) and reproductive decision outcomes on future conception (termination, in vitro fertilisation, use of donor gametes, adoption, or refraining from having children) are needed to better inform recommendations for clinical practice. Any self-reported secondary outcome measures need to use validated instruments. These trials will require longer durations of follow up than previous studies, starting from prepregnancy and lasting into the post-natal period. In the future, rather than offering genetic testing for specific autosomal-recessive conditions, genomic technology, such as pan-ethnic massively parallel sequencing (Bell 2011), may be adopted in which a panel of genetic conditions is identified. However, such trials must also consider the legal, ethical, and cultural barriers to implementation of preconception genetic risk assessment.
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R E F E R E N C E S C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study
Reason for exclusion 
D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S Appendix 1. Glossary
Term Explanation
Antenatal A period during pregnancy and before birth of the child. Carrier (in genetics) An individual who possesses one copy of a mutated allele that causes disease only when two copies are present (an autosomal recessive genetic disorders). A carrier is not affected by the disease, but two carriers can produce a child with the disease Chronic vaso-occlusion Blockage of arteries marked by long duration, by frequent recurrence over a long time, and often by slowly progressing deterioration; having a slow progressive course of indefinite duration Cystic fibrosis transmembrane conductance regulator (CFTR) A protein, involved in the movement of salt across cell membranes, which is lacking or does not function normally in people with cystic fibrosis Diabetes mellitus A pancreatic disorder that causes abnormal insulin production. This affects the body's ability to utilise sugar and other food substances and is usually treated by diet modification (restricted sugar intake) and use of insulin (Continued)
In vivo Inside the living body.
Mutation
A change or alteration of the DNA sequence within a gene.
Nasal epithelium
The tissue that covers and lines the surface of the nose.
Obstructive azoospermia A condition where there is no measurable sperm detected in the semen due to ejaculatory dysfunction or ductal blockage. This condition can occur in people with cystic fibrosis Pancreatic exocrine insufficiency A condition characterized by deficiency of the pancreatic enzymes, resulting in the inability to digest food properly, or maldigestion 
